Lung cancers with exon 20 insertions have a median survival of 16.5 months, shorter than the median survival of 33.0 months in those with common EGFR mutations (A, p=0.06) but similar to the median survival of 20.0 months in EGFR wild-type cancers (B, p=0.60).